CSIMarket
 


Tenx Keane Acquisition  (TENKU)
Other Ticker:  
 

Cumulative Tenx Keane Acquisition's Quick Ratio for Trailing Twelve Months Period

TENKU's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

TENKU Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 502.26 % - - - -
Y / Y Cash & cash equivalent Growth - - - - -
Quick Ratio for Trailing Twelve Months Period 0.5 1.2 2.12 1.5 -
Total Ranking # # # # #
Seq. Current Liabilities Growth 153.56 % 2294395 % - - -
Seq. Cash & cash equivalent Growth -92.83 % 207.45 % -58.37 % - -


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to doubling in Current Liabilities in the III. Quarter to $1 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 0.5 below Tenx Keane Acquisition average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 578 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Tenx Keane Acquisition. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about TENKU
Quick Ratio TENKU in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 579
Sector # 1177
S&P 500 # 4639


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.08 0.84 0.47
(Mar 31 2023)   (Sep 30 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Conduit Pharmaceuticals Inc   1.36 
Precigen Inc   1.35 
Rigel Pharmaceuticals Inc  1.30 
Myovant Sciences Ltd   1.30 
Clever Leaves Holdings Inc   1.28 
Xeris Biopharma Holdings Inc   1.28 
Oncorus Inc   1.25 
Organogenesis Holdings Inc   1.24 
Evotec Se  1.23 
Elite Pharmaceuticals Inc   1.22 
Puma Biotechnology Inc   1.20 
Paratek Pharmaceuticals Inc   1.20 
Celyad Oncology Sa  1.19 
Fortress Biotech Inc   1.19 
Amphastar Pharmaceuticals Inc   1.18 
Entrada Therapeutics Inc   1.17 
Intelgenx Technologies Corp   1.16 
Vaccinex Inc   1.15 
Vbi Vaccines Inc  1.15 
Inflarx N v   1.15 
Harrow Inc   1.15 
Kineta Inc   1.14 
Aldeyra Therapeutics Inc   1.14 
Ainos Inc   1.14 
Evelo Biosciences Inc   1.11 
Nanobiotix S a   1.09 
Sellas Life Sciences Group Inc   1.07 
Evolus Inc   1.07 
Powerup Acquisition Corp   1.06 
Onconova Therapeutics inc   1.05 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com